Equillium is a clinical-stage biotechnology enterprise leveraging a deep scientific understanding of immunobiology to discover, develop, and commercialize novel therapeutic products designed to treat severe autoimmune, inflammatory, and immuno-oncology conditions with high unmet medical needs.